Publication
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerMalignant Lung Neoplasmcivic_curation1.00
- drugGefitinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- geneKRAScivic_curation1.00
- variantEGFR Mutationcivic_curation1.00
- variantKRAS G12Acivic_curation1.00
- variantKRAS G12Ccivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
- variantKRAS G12Scivic_curation1.00
- variantKRAS G12Vcivic_curation1.00
Curated evidence
Evidence citing this paper (8)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 17409929
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR Mutation1 | ||||||||
| Gefitinib | Malignant Lung Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2939In a study of 52 patients with recurrent lung cancer, 27 individuals had EGFR mutation including 2 point mutations in exon 18 (G719A and G1719C), 23 deletions in exon 19, two insertions in exon 19 (I7… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| KRAS G121 | ||||||||
| Gefitinib | Malignant Lung Neoplasm | Predictive | B | Supports Resistance | 2 | submitted | EID2938In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, seven patients with KRAS (G12*) mutations had a lower frequency of partial resp… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| KRAS G12A1 | ||||||||
| Gefitinib | Malignant Lung Neoplasm | Predictive | B | Supports Resistance | 2 | accepted | EID2008In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| KRAS G12C1 | ||||||||
| Gefitinib | Malignant Lung Neoplasm | Predictive | B | Supports Resistance | 2 | accepted | EID2257In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| KRAS G12D2 | ||||||||
| Erlotinib | Malignant Lung Neoplasm | Predictive | B | Supports Resistance | — | submitted | EID3951In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| Gefitinib | Malignant Lung Neoplasm | Predictive | B | Supports Resistance | 2 | accepted | EID2240In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| KRAS G12S1 | ||||||||
| Gefitinib | Malignant Lung Neoplasm | Predictive | B | Supports Resistance | 2 | accepted | EID2273In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |
| KRAS G12V1 | ||||||||
| Gefitinib | Malignant Lung Neoplasm | Predictive | C | Supports Resistance | 2 | accepted | EID2268In recurrent lung cancer patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib, patients with KRAS mutations had a lower frequency of partial response (PR) and… (full text at CIViC) PMID 17409929 · Endoh et al., 2006 · Open in CIViC | civic |